Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

Nature Biotechnology

Volumn 33, Issue 5, 2015, Pages 549-554

  Mailly, Laurent ^a,b   Xiao, Fei ^a,b   Lupberger, Joachim ^a,b   Wilson, Garrick K ^c   Aubert, Philippe ^a,d,e   Duong, François H T ^f   Calabrese, Diego ^f   Leboeuf, Céline ^a,b   Fofana, Isabel ^a,b   Thumann, Christine ^a,b   Bandiera, Simonetta ^a,b   Lütgehetmann, Marc ^g   Volz, Tassilo ^g   Davis, Christopher ^c   Harris, Helen J ^c   Mee, Christopher J ^c   Girardi, Erika ^b,h   Chane Woon Ming, Béatrice ^b,h   Ericsson, Maria ⁱ   Fletcher, Nicola ^c   Bartenschlager, Ralf ^j   Pessaux, Patrick ^a,b,k   Vercauteren, Koen ^l   Meuleman, Philip ^l   Villa, Pascal ^b,m   Kaderali, Lars ⁿ   Pfeffer, Sébastien ^b,h   Heim, Markus H ^f   Neunlist, Michel ^a,d,e   Zeisel, Mirjam B ^a,b   Dandri, Maura ^g   McKeating, Jane A ^c   Robinet, Eric ^a,b   Baumert, Thomas F ^a,b,k   more..

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITÉ DE NANTES   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h INST DE BIOL MOLEC ET CELLULAIRE   (France)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m ULP Strasbourg Faculté de Pharmacie   (France)

ⁿ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL SIGNALING; MAMMALS; MONOCLONAL ANTIBODIES; PROTEINS; VIRUSES;

ANTIVIRAL THERAPY; CELL TRANSMISSIONS; CHRONIC INFECTION; HEPATITIS C VIRUS; LIVER CIRRHOSIS; SIGNALING EVENTS; TIGHT JUNCTIONS; VIRAL INFECTIONS;

ANTIBODIES;

CLAUDIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TJ PROTEIN CLAUDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGOLD LABELING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; VIRAL CLEARANCE; VIRUS INHIBITION; ANIMAL; HEPACIVIRUS; IMMUNOLOGY; LIVER CELL; LIVER CIRRHOSIS; PATHOGENICITY; VIROLOGY;

HEPATITIS C VIRUS; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLAUDIN-1; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; MICE;

EID: 84929160912     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3179     Document Type: Article

References (37)

1. Thomas, D.L. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19, 850-858 (2013).
2. Evans, M.J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007).
3. Cohen, C.J. et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA 98, 15191-15196 (2001).
4. Fukumatsu, M. et al. Shigella targets epithelial tricellular junctions and uses a noncanonical clathrin-dependent endocytic pathway to spread between cells. Cell Host Microbe 11, 325-336 (2012).
5. Che, P., Tang, H. & Li, Q. The interaction between claudin-1 and dengue viral prM/M protein for its entry. Virology 446, 303-313 (2013).
6. Mercer, D.F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7, 927-933 (2001).
7. Fofana, I. et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139, 953-964 (2010).
8. Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25-27 (2008).
9. Lupberger, J. et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17, 589-595 (2011).
10. Meuleman, P. et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55, 364-372 (2012).
11. Shi, N. et al. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62, 1055-1061 (2013).
12. Harris, H.J., Wilson, G.K., Hubscher, S.G. & McKeating, J.A. Heterogeneous claudin-1 expression in human liver. Hepatology 57, 854-855 (2013).
13. Fletcher, N.F. et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 59, 1320-1330 (2014).
14. Bukh, J. et al. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J. Infect. Dis. 201, 1381-1389 (2010).
15. Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103, 7408-7413 (2006).
16. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
17. Fofana, I. et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143, 223-233 (2012).
18. Krieger, S.E. et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51, 1144-1157 (2010).
19. Dübel, S. & Reichert, J.M. (eds.). Handbook of Therapeutic Antibodies (Wiley-Blackwell, 2014).
20. Harris, H.J. et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 285, 21092-21102 (2010).
21. Suh, Y. et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32, 4873-4882 (2013).
22. Brazzoli, M. et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82, 8316-8329 (2008).
23. Diao, J. et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 86, 10935-10949 (2012).
24. Zona, L. et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13, 302-313 (2013).
25. Menzel, N. et al. MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 8, e1002829 (2012).
26. Wieland, S. et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59, 2121-2130 (2014).
27. Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107 (1998).
28. Lan, L. et al. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J. Immunol. 181, 4926-4935 (2008).
29. Haid, S. et al. Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology 59, 24-34 (2014).
30. Fofana, I. et al. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J. Virol. 87, 10405-10410 (2013).
31. Reynolds, G.M. et al. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47, 418-427 (2008).
32. Koutsoudakis, G., Herrmann, E., Kallis, S., Bartenschlager, R. & Pietschmann, T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81, 588-598 (2007).
33. Harris, H.J. et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J. Virol. 82, 5007-5020 (2008).
34. Piche, T. et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58, 196-201 (2009).
35. Zahid, M.N. et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57, 492-504 (2013).
36. Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26, 335-341 (2008).
37. Dill, M.T. et al. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 143, 777-786 (2012).